Acetate
- Generic Name
- Acetate
- Drug Type
- Small Molecule
- Chemical Formula
- C2H3O2
- CAS Number
- 71-50-1
- Unique Ingredient Identifier
- 569DQM74SC
Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: a Pilot Study
Phase 4
Not yet recruiting
- Conditions
- Postpartum ContraceptionDepot Medroxyprogesterone AcetateLactationDMPA
- Interventions
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 40
- Registration Number
- NCT06816901
- Locations
- 🇳🇵
Provincial Hospital Janakpur of Dhanusha district, Janakpur, Dhanusha district, Nepal
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
Phase 4
Not yet recruiting
- Conditions
- Perioperative Volume ReplacementHydroxyethyl Starch
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 410
- Registration Number
- NCT06663254
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University;, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Phase 1
Not yet recruiting
- Conditions
- Alzheimer DiseaseMild Cognitive Impairment
- Interventions
- Other: Placebo
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- MTI Biotech Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06432166
- Locations
- 🇺🇸
Center for Cognitive Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Phase 2
Recruiting
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRIP1 Gene MutationRAD51B Gene MutationRAD54L Gene MutationCHEK2 Gene MutationFANCA Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationPALB2 Gene Mutation
- Interventions
- Drug: Androgen Deprivation Therapy (ADT)
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Qian Qin
- Target Recruit Count
- 64
- Registration Number
- NCT06392841
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Phase 1
Recruiting
- Conditions
- Overweight and ObesityNon-Alcoholic Fatty Liver DiseaseInsulin ResistancePrediabetic State
- Interventions
- Drug: PlaceboDietary Supplement: Nestlé BOOST Plus
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 32
- Registration Number
- NCT06354088
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Phase 2
Recruiting
- Conditions
- Oligometastatic DiseaseProstate Cancer
- Interventions
- Radiation: Stereotactic ablative radiation therapy (SABR)Drug: Androgen deprivation therapy (ADT)
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 88
- Registration Number
- NCT06212583
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery
Phase 3
Completed
- Conditions
- Endometriosis Ovary
- Interventions
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitas Diponegoro
- Target Recruit Count
- 80
- Registration Number
- NCT06145438
- Locations
- 🇮🇩
Kariadi Hospital, Semarang, Central Java, Indonesia
Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles
Not Applicable
Completed
- Conditions
- Infertility
- Interventions
- Drug: Gonadotropin releasing hormone antagonist (Cetrotide)
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Bezmialem Vakif University
- Target Recruit Count
- 297
- Registration Number
- NCT05767086
- Locations
- 🇹🇷
Bezmialem Vakif University, Istanbul, Turkey
Acetated Ringer´s Solution in Experimental Hypovolemia
Phase 4
Recruiting
- Conditions
- HypovolemiaFluid LossHemodynamic Instability
- Interventions
- Other: Lower body negative pressure
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05705115
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Phase 1
Active, not recruiting
- Conditions
- Metastatic Prostate CancerNon-metastatic Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Praful Ravi, MB BCHir, MRCP
- Target Recruit Count
- 9
- Registration Number
- NCT05617885
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath